Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 20/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 20/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL508089 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL7468012 | 0.99 | CHRM2 (0.98) | CHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL27503837 | 0.99 | CHRM2 (0.98) | CHRM2CHRM1CHRM3 | |
| SCHEMBL7465278 | 0.95 | CHRM2 (0.90) | CHRM2CHRM1CHRM3 | |
| SCHEMBL27521643 | 0.95 | CHRM2 (0.90) | CHRM2CHRM1CHRM3 | |
| SCHEMBL27521507 | 0.94 | CHRM2 (0.89) | CHRM2CHRM1CHRM3 | |
| SCHEMBL7472883 | 0.94 | CHRM2 (0.89) | CHRM2CHRM1CHRM3 | |
| SCHEMBL7467386 | 0.93 | CHRM2 (0.88) | CHRM2CHRM1CHRM3 | |
| SCHEMBL7467128 | 0.90 | CHRM2 (1.00) | CHRM2CHRM1CHRM3 | |
| SCHEMBL27503115 | 0.90 | CHRM2 (1.00) | CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2828242-B1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE ß2 ADRENERGIC RECEPTOR. | ALMIRALL SA (ES) | 2017-10-04 | — | — | EP | claimed |
| US-9346759-B2 | Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2016-05-24 | — | — | US | claimed |
| US-20150065471-A1 | SALTS OF 5-[(1R)-2-(AMINO)-1-HYDROXYETHYL]-8-HYDROXYQUINOLIN-2(1H)-ONE | ALMIRALL, S.A. (ES) | 2015-03-05 | — | — | US | claimed |
| US-20150057256-A1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2--1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYTLATE AS AGONIST OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL S.A. (ES) | 2015-02-26 | — | — | US | claimed |
| EP-2828242-A1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE ß2 ADRENERGIC RECEPTOR. | Almirall S.A. (ES) | 2015-01-28 | — | — | EP | claimed |
| US-8563731-B2 | Mesylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]jamino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2013-10-22 | — | — | US | claimed |
| EP-2647627-A1 | Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one. | Almirall, S.A. (ES) | 2013-10-09 | — | — | EP | claimed |
| WO-2013139712-A1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE β2 ADRENERGIC RECEPTOR. | ALMIRALL, S.A. (ES) | 2013-09-26 | — | — | WO | claimed |
| EP-2641900-A1 | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. | Almirall, S.A. (ES) | 2013-09-25 | — | — | EP | claimed |
| EP-2367796-B1 | MESYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO }-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2012-10-24 | — | — | EP | claimed |
| EP-2121615-B1 | NAPADISYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2012-03-28 | — | — | EP | claimed |
| US-20110251234-A1 | MESYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2011-10-13 | — | — | US | claimed |
| EP-2367796-A1 | MESYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO }-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | Almirall, S.A. (ES) | 2011-09-28 | — | — | EP | claimed |
| US-20110195943-A9 | NAPADISYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2011-08-11 | — | — | US | claimed |
| WO-2010072354-A1 | MESYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO }-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE β2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2010-07-01 | — | — | WO | claimed |
| US-20100093681-A1 | NAPADISYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2010-04-15 | — | — | US | claimed |
| EP-2121615-A1 | NAPADISYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | Almirall, S.A. (ES) | 2009-11-25 | — | — | EP | claimed |
| WO-2008095720-A1 | NAPADISYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2008-08-14 | — | — | WO | claimed |
| CN-1226888-A | Fluorinated 1,4-disubstituted piperidine derivatives | BANYU PHARMA CO LTD (JP) | 1999-08-25 | — | — | CN | claimed |
| EP-2828242-B1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE ß2 ADRENERGIC RECEPTOR. | ALMIRALL SA (ES) | 2017-10-04 | — | — | EP | disclosed |
| US-20160303108-A1 | NOVEL DOSAGE FORM AND FORMULATION OF ABEDITEROL | ALMIRALL SA (ES) | 2016-10-20 | — | — | US | disclosed |
| US-9388189-B2 | Pyrrolotriazinone derivatives as PI3K inhibitors | ALMIRALL, S.A. (ES) | 2016-07-12 | — | — | US | disclosed |
| US-9346759-B2 | Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2016-05-24 | — | — | US | disclosed |
| US-9340547-B2 | Pyrrolotriazinone derivatives as inhibitors P13K | ALMIRALL, S.A. (ES) | 2016-05-17 | — | — | US | disclosed |
| EP-2702061-B9 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL SA (ES) | 2016-02-24 | — | — | EP | disclosed |
| US-9206183-B2 | Substituted pyrazolo[1,5-a]pyridines as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-12-08 | — | — | US | disclosed |
| US-20150291595-A1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2015-10-15 | — | — | US | disclosed |
| US-9133200-B2 | Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-09-15 | — | — | US | disclosed |
| EP-2909207-A1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | Almirall S.A. (ES) | 2015-08-26 | — | — | EP | disclosed |
| US-20150210643-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | LABORATORIOS ALMIRALL, S.A. | 2015-07-30 | — | — | US | disclosed |
| EP-2702061-B1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL SA (ES) | 2015-07-29 | — | — | EP | disclosed |
| WO-2015091531-A1 | IMIDAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2015-06-25 | — | — | WO | disclosed |
| US-20150140099-A1 | NOVEL DOSAGE FORM AND FORMULATION OF ABEDITEROL | ALMIRALL, S.A. (ES) | 2015-05-21 | — | — | US | disclosed |
| US-9034311-B2 | Pyridin-2(1 H)-one derivatives as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-05-19 | — | — | US | disclosed |
| US-20150118186-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL SA (ES) | 2015-04-30 | — | — | US | disclosed |
| EP-2848615-A1 | New pyrazole derivatives as CRAC channel modulators | Almirall, S.A. (ES) | 2015-03-18 | — | — | EP | disclosed |
| US-20150057256-A1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2--1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYTLATE AS AGONIST OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL S.A. (ES) | 2015-02-26 | — | — | US | disclosed |
| EP-2828242-A1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE ß2 ADRENERGIC RECEPTOR. | Almirall S.A. (ES) | 2015-01-28 | — | — | EP | disclosed |
| US-20140343097-A1 | 5-(2-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE FOR THE TREATMENT OF LUNG FUNCTION | ALMIRALL, S.A. (ES) | 2014-11-20 | — | — | US | disclosed |
| US-20140271543-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2014-09-18 | — | — | US | disclosed |
| US-8772288-B2 | Substituted spiro[cycloalkyl-1,3′-indo]-2′(1′H)-one derivatives and their use as P38 mitogen-activated kinase inhibitors | ALMIRALL, S.A. (ES) | 2014-07-08 | — | — | US | disclosed |
| US-20140170110-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES | ALMIRALL, S.A. (ES) | 2014-06-19 | — | — | US | disclosed |
| EP-2738172-A1 | New bicyclic compounds as crac channel modulators | Almirall, S.A. (ES) | 2014-06-04 | — | — | EP | disclosed |
| WO-2014060432-A1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060431-A1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2014-04-24 | — | — | WO | disclosed |
| EP-2702061-A1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | Almirall S.A. (ES) | 2014-03-05 | — | — | EP | disclosed |
| US-20140038928-A1 | 5-(2--1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2 (1H)-ONE AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES | ALMIRALL, S.A. (ES) | 2014-02-06 | — | — | US | disclosed |
| EP-2668941-A1 | Novel dosage form and formulation of abediterol | Almirall, S.A. (ES) | 2013-12-04 | — | — | EP | disclosed |
| US-20130309200-A1 | IMIDAZO [1,2-B] PYRIDAZINE AND IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-11-21 | — | — | US | disclosed |
| EP-2280943-B1 | NEW SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDO]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL SA (ES) | 2013-11-06 | — | — | EP | disclosed |
| US-8563731-B2 | Mesylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]jamino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2013-10-22 | — | — | US | disclosed |
| EP-2647627-A1 | Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one. | Almirall, S.A. (ES) | 2013-10-09 | — | — | EP | disclosed |
| EP-2643321-A1 | IMIDAZO [1,2-B]PYRIDAZINE AND IMIDAZO [4,5-B]PYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2013-10-02 | — | — | EP | disclosed |
| WO-2013139712-A1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE β2 ADRENERGIC RECEPTOR. | ALMIRALL, S.A. (ES) | 2013-09-26 | — | — | WO | disclosed |
| EP-2641900-A1 | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. | Almirall, S.A. (ES) | 2013-09-25 | — | — | EP | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| EP-2398473-B1 | 5-(2-{[6-(2, 2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2-(1H)-one for the treatment of lung function | ALMIRALL SA (ES) | 2013-07-24 | — | — | EP | disclosed |
| US-8450341-B2 | Substituted indolin-2-one derivatives and their use as P38 mitogen-activated kinase inhibitors | ALMIRALL, S.A. (ES) | 2013-05-28 | — | — | US | disclosed |
| US-8420669-B2 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the BETA2 adrenergic receptor | LABORATORIES ALMIRALL, S.A. (ES) | 2013-04-16 | — | — | US | disclosed |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-04-11 | — | — | US | disclosed |
| EP-2554544-A1 | Pyridin-2(1h)-one derivatives as jak inhibitors | Almirall, S.A. (ES) | 2013-02-06 | — | — | EP | disclosed |
| WO-2013010880-A1 | NEW CRTH2 ANTAGONISTS | ALMIRALL, S.A. (ES) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013010881-A1 | NEW CRTh2 ANTAGONISTS | ALMIRALL, S.A. (ES) | 2013-01-24 | — | — | WO | disclosed |
| EP-2548876-A1 | New CRTh2 antagonists | Almirall, S.A. (ES) | 2013-01-23 | — | — | EP | disclosed |
| EP-2548863-A1 | New CRTh2 antagonists. | Almirall, S.A. (ES) | 2013-01-23 | — | — | EP | disclosed |
| EP-2536728-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-12-26 | — | — | EP | disclosed |
| US-8334294-B2 | 4,8-diphenyl-polyazanaphthalene derivatives | ALMIRALL, S.A. (ES) | 2012-12-18 | — | — | US | disclosed |
| WO-2012160030-A1 | PYRIDIN-2 (1H) -ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES | ALMIRALL, S.A. (ES) | 2012-11-29 | — | — | WO | disclosed |
| EP-2526945-A1 | New CRTH2 Antagonists | Almirall, S.A. (ES) | 2012-11-28 | — | — | EP | disclosed |
| WO-2012146667-A1 | IMIDAZOPYRIDINE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012146666-A1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2012-11-01 | — | — | WO | disclosed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| EP-2518070-A1 | Pyrrolotriazinone derivatives as PI3K inhibitors | Almirall, S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| EP-2367796-B1 | MESYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO }-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2012-10-24 | — | — | EP | disclosed |
| US-8283342-B2 | Napadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor | ALMIRALL S.A. (ES) | 2012-10-09 | — | — | US | disclosed |
| EP-2498775-A1 | NEW 7-PHENYL-[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3(2H)-ONE DERIVATIVES | Almirall S.A. (ES) | 2012-09-19 | — | — | EP | disclosed |
| US-20120225904-A1 | New 7-Phenyl-[1,2,4]triazolo[4,3-a]Pyridin-3(2H)-One Derivatives | ALMIRALL, S.A. (ES) | 2012-09-06 | — | — | US | disclosed |
| US-8258122-B2 | 3-([1,2,4]triazolo[4,3-a]pyridin-7-yl)benzamide derivatives | ALMIRALL, S.A. (ES) | 2012-09-04 | — | — | US | disclosed |
| EP-2489663-A1 | Compounds as syk kinase inhibitors | Almirall, S.A. (ES) | 2012-08-22 | — | — | EP | disclosed |
| EP-2146988-B1 | NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES | ALMIRALL SA (ES) | 2012-08-15 | — | — | EP | disclosed |
| EP-2463289-A1 | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2012-06-13 | — | — | EP | disclosed |
| WO-2012069202-A1 | IMIDAZO [1,2-B] PYRIDAZINE AND IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL,S.A. (ES) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012069175-A1 | NEW PYRAZOLE DERIVATIVES HAVING CRTH2 ANTAGONISTIC BEHAVIOUR | ALMIRALL, S.A. (ES) | 2012-05-31 | — | — | WO | disclosed |
| EP-2457900-A1 | New pyrazole derivatives having CRTh2 antagonistic behaviour | Almirall, S.A. (ES) | 2012-05-30 | — | — | EP | disclosed |
| US-8178679-B2 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptors | ALMIRALL, S.A. (ES) | 2012-05-15 | — | — | US | disclosed |
| US-20120115826-A2 | Derivatives of 4-(2-Amino-1-Hydroxyethyl) Phenol as Agonists of the Beta2 AdrenergicReceptor | LABORATORIOS ALMIRALL, S.A. (ES) | 2012-05-10 | — | — | US | disclosed |
| EP-2280953-B1 | NEW SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL SA (ES) | 2012-05-09 | — | — | EP | disclosed |
| US-20120101075-A2 | Derivatives of 4-(2-Amino-1-Hydroxyethyl) Phenol as Agonists of the Beta2 Adrenergic Receptor | LABORATORIOS ALMIRALL, S.A. (ES) | 2012-04-26 | — | — | US | disclosed |
| EP-2441755-A1 | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors | Almirall, S.A. (ES) | 2012-04-18 | — | — | EP | disclosed |
| WO-2012041476-A1 | PYRIDINE AND ISOQUINOLINE DERIVATIVES AS SYK- AND JAK-KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2012-04-05 | — | — | WO | disclosed |
| EP-2121615-B1 | NAPADISYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2012-03-28 | — | — | EP | disclosed |
| US-20120040941-A1 | 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES | ALMIRALL, S.A. (ES) | 2012-02-16 | — | — | US | disclosed |
| US-20120029014-A1 | 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2 (1H)-ONE FOR THE TREATMENT OF LUNG FUNCTION | ALMIRALL, S.A. (ES) | 2012-02-02 | — | — | US | disclosed |
| EP-2397482-A1 | Heteroaryl imidazolone derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-12-21 | — | — | EP | disclosed |
| EP-2394998-A1 | 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors | Almirall, S.A. (ES) | 2011-12-14 | — | — | EP | disclosed |
| EP-2013183-B1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2011-11-02 | — | — | EP | disclosed |
| EP-2380890-A1 | New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors | Almirall, S.A. (ES) | 2011-10-26 | — | — | EP | disclosed |
| US-20110253549-A1 | WASHING APPARATUS AND METHOD OF DEODORIZING WASHING WATER | KANNO MINORU | 2011-10-20 | — | — | US | disclosed |
| US-20110251234-A1 | MESYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2011-10-13 | — | — | US | disclosed |
| EP-2367796-A1 | MESYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO }-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | Almirall, S.A. (ES) | 2011-09-28 | — | — | EP | disclosed |
| WO-2011101161-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-08-25 | — | — | WO | disclosed |
| EP-2360158-A1 | Pyrazole derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-08-24 | — | — | EP | disclosed |
| US-20110195943-A9 | NAPADISYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2011-08-11 | — | — | US | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| EP-2338888-A1 | Imidazopyridine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2011-06-29 | — | — | EP | disclosed |
| US-7964615-B2 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2011-06-21 | — | — | US | disclosed |
| WO-2011057757-A1 | NEW 7-PHENYL-[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3(2H)-ONE DERIVATIVES | ALMIRALL, S.A. (ES) | 2011-05-19 | — | — | WO | disclosed |
| EP-2322176-A1 | New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives | Almirall, S.A. (ES) | 2011-05-18 | — | — | EP | disclosed |
| US-20110053936-A1 | SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2011-03-03 | — | — | US | disclosed |
| US-20110046097-A1 | SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2011-02-24 | — | — | US | disclosed |
| EP-2280953-A1 | NEW SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | Almirall, S.A. (ES) | 2011-02-09 | — | — | EP | disclosed |
| EP-2280943-A1 | NEW SUBSTITUTED SPIROÝCYCLOALKYL-1,3'-INDOL¨-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS. | Almirall, S.A. (ES) | 2011-02-09 | — | — | EP | disclosed |
| US-20100324000-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTORS | ALMIRALL, S.A. (ES) | 2010-12-23 | — | — | US | disclosed |
| EP-2263998-A1 | Derivatives of 4-(2-amino-1-hydroxyethyl) phenol as agonists of the beta2 adrenergic receptor | Almirall S.A. (ES) | 2010-12-22 | — | — | EP | disclosed |
| EP-2254860-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL) PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | Almirall, S.A. (ES) | 2010-12-01 | — | — | EP | disclosed |
| US-20100273757-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. | 2010-10-28 | — | — | US | disclosed |
| EP-2226323-A1 | New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives | Almirall, S.A. (ES) | 2010-09-08 | — | — | EP | disclosed |
| US-7790728-B2 | Pyrazine derivatives useful as adenosine receptor antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-09-07 | — | — | US | disclosed |
| WO-2010097172-A1 | NEW TETRAHYDROPYRAZOLO[3,4-C]ISOQUINOLIN-5-AMINE DERIVATIVES | ALMIRALL, S.A. (ES) | 2010-09-02 | — | — | WO | disclosed |
| EP-2057122-B1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE 2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2010-09-01 | — | — | EP | disclosed |
| EP-2221055-A1 | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function | Almirall, S.A. (ES) | 2010-08-25 | — | — | EP | disclosed |
| EP-2221297-A1 | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases | Almirall, S.A. (ES) | 2010-08-25 | — | — | EP | disclosed |
| EP-2212276-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | Almirall, S.A. (ES) | 2010-08-04 | — | — | EP | disclosed |
| WO-2010072354-A1 | MESYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO }-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE β2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2010-07-01 | — | — | WO | disclosed |
| US-20100168161-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-07-01 | — | — | US | disclosed |
| EP-2196465-A1 | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors | Almirall, S.A. (ES) | 2010-06-16 | — | — | EP | disclosed |
| US-20100137399-A1 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR URINE COLLECTION DISORDER ACCOMPANYING LOWER URINARY TRACT OBSTRUCTION | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100130517-A1 | NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES | ALMIRALL, S.A. (ES) | 2010-05-27 | — | — | US | disclosed |
| US-20100120731-A1 | 3-([1,2,4]TRIAZOLO [4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVES | ALMIRALL, S.A. (ES) | 2010-05-13 | — | — | US | disclosed |
| US-20100093681-A1 | NAPADISYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2010-04-15 | — | — | US | disclosed |
| EP-2146988-A1 | NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES | Almirall, S.A. (ES) | 2010-01-27 | — | — | EP | disclosed |
| EP-2121615-A1 | NAPADISYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | Almirall, S.A. (ES) | 2009-11-25 | — | — | EP | disclosed |
| EP-2118100-A1 | NEW 3- ([1,2,4] TRIAZOLO [4,3-A] PYRIDIN-7-YL)BENZAMIDE DERIVATIVES | Almirall, S.A. (ES) | 2009-11-18 | — | — | EP | disclosed |
| WO-2009132774-A1 | NEW SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P39 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S. A. (ES) | 2009-11-05 | — | — | WO | disclosed |
| EP-2113503-A1 | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors | Laboratorios Almirall, S.A. (ES) | 2009-11-04 | — | — | EP | disclosed |
| WO-2009124692-A1 | NEW SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS. | ALMIRALL, S.A. (ES) | 2009-10-15 | — | — | WO | disclosed |
| EP-2108641-A1 | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors | Laboratorios Almirall, S.A. (ES) | 2009-10-14 | — | — | EP | disclosed |
| US-20090227651-A1 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR URINE COLLECTION DISORDER ACCOMPANYING LOWER URINARY TRACT OBSTRUCTION | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| WO-2009106351-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL) PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2009-09-03 | — | — | WO | disclosed |
| EP-2096105-A1 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor | Laboratorios Almirall, S.A. (ES) | 2009-09-02 | — | — | EP | disclosed |
| WO-2009068177-A1 | DERIVATIVES OF 4-(2-AMINO-1 -HYDROXYETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2009-06-04 | — | — | WO | disclosed |
| EP-2057122-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE 2 ADRENERGIC RECEPTOR | Laboratorios Almirall, S.A. (ES) | 2009-05-13 | — | — | EP | disclosed |
| US-20090082378-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-03-26 | — | — | US | disclosed |
| US-20090042933-A1 | Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the Beta2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| US-20090042891-A1 | Pyrazine Derivatives Useful as Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| EP-2013183-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | Laboratorios Almirall, S.A. (ES) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008131922-A1 | NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES | ALMIRALL, S.A. (ES) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008107125-A1 | NEW 3-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVES | ALMIRALL, S.A. (ES) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008095720-A1 | NAPADISYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2008-08-14 | — | — | WO | disclosed |
| EP-1922313-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | Laboratorios Almirall, S.A. (ES) | 2008-05-21 | — | — | EP | disclosed |
| WO-2008046598-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-04-24 | — | — | WO | disclosed |
| EP-1885684-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA-2 ADRENERGIC RECEPTOR | Laboratorios Almirall, S.A. (ES) | 2008-02-13 | — | — | EP | disclosed |
| US-20070270459-A1 | Overactive bladder treating drug | ASTELLAS PHARMA INC. (JP) | 2007-11-22 | — | — | US | disclosed |
| WO-2007124898-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR | LABORATORIOS, ALMIRALL S.A. (ES) | 2007-11-08 | — | — | WO | disclosed |
| EP-1800677-A1 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR URINE COLLECTION DISORDER ACCOMPANYING LOWER URINARY TRACT OBSTRUCTION | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-06-27 | — | — | EP | disclosed |
| WO-2007017096-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-02-15 | — | — | WO | disclosed |
| WO-2006122788-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-11-23 | — | — | WO | disclosed |
| US-20060035923-A1 | Overactive bladder treating drug | ASTELLAS PHARMA INC. (JP) | 2006-02-16 | — | — | US | disclosed |
| EP-1552825-A1 | THERAPEUTIC AGENT FOR OVERACTIVE BLADDER | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
| EP-1552825-A1 | THERAPEUTIC AGENT FOR OVERACTIVE BLADDER | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (36 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270459-A1 | Overactive bladder treating drug | ADRB2, BPHL, ADRA1B | CHRM2 95/4885CHRM1 303/4885CHRM3 90/4885 |
| US-20100137399-A1 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR URINE COLLECTION DISORDER ACCOMPANYING LOWER URINARY TRACT OBSTRUCTION | IDUA, AADAT, REN | CHRM2 291/4885CHRM1 272/4885CHRM3 143/4885 |
| US-20140170110-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES | JAK1, JAK3, JAK2 | CHRM2 2241/4885CHRM1 2056/4885CHRM3 3355/4885 |
| US-20140038928-A1 | 5-(2--1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2 (1H)-ONE AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES | ADRB2, ADRA2C, ADRB1 | CHRM2 25/4885CHRM1 16/4885CHRM3 23/4885 |
| US-20120040941-A1 | 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES | ADRB2, ADRA2C, ADRB1 | CHRM2 24/4885CHRM1 16/4885CHRM3 22/4885 |
| US-20110251234-A1 | MESYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA2 ADRENERGIC RECEPTOR | ADRB2, ADRA2C, ADRA2A | CHRM2 74/4885CHRM1 112/4885CHRM3 73/4885 |
| US-20060035923-A1 | Overactive bladder treating drug | ADRB2, BPHL, ADRA1B | CHRM2 95/4885CHRM1 303/4885CHRM3 90/4885 |
| US-20150118186-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | CHRM2 4869/4885CHRM1 4865/4885CHRM3 4767/4885 |
| US-20090042891-A1 | Pyrazine Derivatives Useful as Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA3 | CHRM2 138/4885CHRM1 310/4885CHRM3 665/4885 |
| US-20100168161-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ADRB2, ADRB1, ADRA2C | CHRM2 23/4885CHRM1 41/4885CHRM3 33/4885 |
| US-20140343097-A1 | 5-(2-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE FOR THE TREATMENT OF LUNG FUNCTION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B2, CYP27A1 | CHRM2 563/4885CHRM1 305/4885CHRM3 279/4885 |
| US-20100324000-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTORS | ADRB2, ADRB1, ADRA2C | CHRM2 39/4885CHRM1 69/4885CHRM3 47/4885 |
| US-20120029014-A1 | 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2 (1H)-ONE FOR THE TREATMENT OF LUNG FUNCTION | SULT1E1, SULT2A1, UGT1A1 | CHRM2 437/4885CHRM1 248/4885CHRM3 241/4885 |
| US-20150140099-A1 | NOVEL DOSAGE FORM AND FORMULATION OF ABEDITEROL | SLC6A11, SLC6A1, SLC6A13 | CHRM2 14/4885CHRM1 62/4885CHRM3 7/4885 |
| US-20100130517-A1 | NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES | MAPK8, MAPK4, MAP3K8 | CHRM2 4499/4885CHRM1 4686/4885CHRM3 4571/4885 |
| US-20120225904-A1 | New 7-Phenyl-[1,2,4]triazolo[4,3-a]Pyridin-3(2H)-One Derivatives | MAPK7, MAPK1, MAP3K7 | CHRM2 2821/4885CHRM1 2619/4885CHRM3 2364/4885 |
| US-20150291595-A1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | PIK3CB, PIK3CD, PIK3CA | CHRM2 4874/4885CHRM1 4860/4885CHRM3 4849/4885 |
| US-20100120731-A1 | 3-([1,2,4]TRIAZOLO [4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVES | MAP4K2, MAP3K7, MAPK7 | CHRM2 2769/4885CHRM1 3133/4885CHRM3 2481/4885 |
| US-20100273757-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | CHRM2 66/4885CHRM1 117/4885CHRM3 103/4885 |
| US-20090042933-A1 | Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the Beta2 adrenergic receptor | ADRB2, ADRA2C, ADRB1 | CHRM2 8/4885CHRM1 12/4885CHRM3 14/4885 |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | CHRM2 4832/4885CHRM1 4807/4885CHRM3 4796/4885 |
| US-20110046097-A1 | SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | MAPK1, MAPKAPK2, MAPK7 | CHRM2 2302/4885CHRM1 2062/4885CHRM3 2886/4885 |
| US-20090082378-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | ADRB2, ADRA2C, ADRB1 | CHRM2 47/4885CHRM1 62/4885CHRM3 64/4885 |
| US-20120115826-A2 | Derivatives of 4-(2-Amino-1-Hydroxyethyl) Phenol as Agonists of the Beta2 AdrenergicReceptor | ADRB2, ADRB1, ADRA2C | CHRM2 35/4885CHRM1 42/4885CHRM3 40/4885 |
| US-20150057256-A1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2--1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYTLATE AS AGONIST OF THE BETA2 ADRENERGIC RECEPTOR | ADRA2C, ADRB2, ADRA2A | CHRM2 45/4885CHRM1 73/4885CHRM3 43/4885 |
| US-20100093681-A1 | NAPADISYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ADRA2C, ADRB2, ADRA2A | CHRM2 126/4885CHRM1 147/4885CHRM3 137/4885 |
| US-20160303108-A1 | NOVEL DOSAGE FORM AND FORMULATION OF ABEDITEROL | GPBAR1, GCGR, PTGIR | CHRM2 129/4885CHRM1 374/4885CHRM3 107/4885 |
| US-20150210643-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ADRB2, ADRB1, ADRA2C | CHRM2 23/4885CHRM1 41/4885CHRM3 33/4885 |
| US-20110195943-A9 | NAPADISYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ADRA2C, ADRB2, ADRA2A | CHRM2 126/4885CHRM1 147/4885CHRM3 137/4885 |
| US-20110053936-A1 | SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | CHRM2 3372/4885CHRM1 3221/4885CHRM3 3241/4885 |
| US-20150065471-A1 | SALTS OF 5-[(1R)-2-(AMINO)-1-HYDROXYETHYL]-8-HYDROXYQUINOLIN-2(1H)-ONE | SULT2A1, SULT1E1, SULT1A1 | CHRM2 2643/4885CHRM1 1623/4885CHRM3 2943/4885 |
| US-20140271543-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | CHRM2 3718/4885CHRM1 3326/4885CHRM3 4123/4885 |
| US-20120101075-A2 | Derivatives of 4-(2-Amino-1-Hydroxyethyl) Phenol as Agonists of the Beta2 Adrenergic Receptor | ADRB2, ADRB1, ADRA2C | CHRM2 41/4885CHRM1 64/4885CHRM3 48/4885 |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | JAK2, JAK1, JAK3 | CHRM2 4853/4885CHRM1 4870/4885CHRM3 4805/4885 |
| US-20130309200-A1 | IMIDAZO [1,2-B] PYRIDAZINE AND IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | CHRM2 4237/4885CHRM1 3798/4885CHRM3 4432/4885 |
| US-20090227651-A1 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR URINE COLLECTION DISORDER ACCOMPANYING LOWER URINARY TRACT OBSTRUCTION | REN, OPRD1, IDO1 | CHRM2 149/4885CHRM1 124/4885CHRM3 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.